Personalized medicine tailors therapies, disease prevention, and health maintenance to the
individual, with pharmacogenomics serving as a key tool to improve outcomes and prevent …

The clinical definition of neurodegenerative diseases is based on symptoms that reflect
terminal damage of specific brain regions. This is misleading as it tells little about the initial …

Cell type-specific transcriptional differences between brain tissues from donors with
Alzheimer's disease (AD) and unaffected controls have been well documented, but few …

Progressive supranuclear palsy (PSP) is a neurodegenerative parkinsonian disorder
characterized by cell-type-specific tau lesions in neurons and glia. Prior work uncovered …

Nucleotide changes in gene regulatory elements are important determinants of neuronal
development and diseases. Using massively parallel reporter assays in primary human cells …

Progressive supranuclear palsy (PSP), a rare Parkinsonian disorder, is characterized by
problems with movement, balance, and cognition. PSP differs from Alzheimer's disease (AD) …

The burden of human disease lies predominantly in polygenic diseases. Since the early
2000s, genome-wide association studies (GWAS) have identified genetic variants and loci …

Comparative studies of hominids have long sought to identify mutational events that shaped
the evolution of the human nervous system. However, functional genetic differences are …

Microglia, the macrophages of the brain, are vital for brain homeostasis and have been
implicated in a broad range of brain disorders. Neuroinflammation has gained traction as a …

Tauopathies are a group of neurodegenerative diseases defined by abnormal aggregates of
tau, a microtubule-associated protein encoded by MAPT. MAPT expression is near absent in …